Company Foundation

Established company with co-founders Dr. Charles Nichols, Dr. David Nichols, Dr. Timothy Foster, and Alex Speiser.\r\n\r\nDr. David Nichols defined serotonin 2A receptors’ therapeutic role in psychiatry, publishing the first paper on MDMA, and responsible for psychedelic IP being used in the clinic today (i.e. Compass Pathways).\r\n\r\nCharles discovered 2A activation drives potent anti-inflammatory effects in asthma, cardiovascular, and autoimmune disease models, building upon his earlier efficacy work in models of neuropsychology.\r\n\r\nWith Dr. Timothy Foster, they confirmed 2A’s therapeutic impact in further inflammatory, ocular, and neurodegenerative disease models.\r\n